Comparison of Clinical Outcomes Following Gel Stent Implantation via Ab-Externo and Ab-Interno Approaches in Patients with Refractory Glaucoma
Mark J Gallardo,Logan R Vincent,Matthew Porter
DOI: https://doi.org/10.2147/OPTH.S354038
2022-07-06
Clinical Ophthalmology
Abstract:Mark J Gallardo, 1– 3 Logan R Vincent, 1 Matthew Porter 2 1 El Paso Eye Surgeons, El Paso, TX, USA; 2 Department of Ophthalmology, Texas Tech University School of Medicine, Lubbock, TX, USA; 3 Department of Ophthalmology, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USA Correspondence: Mark J Gallardo, El Paso Eye Surgeons, 1201 N Mesa St, Ste G, El Paso, TX, 79902, USA, Tel +1 915 542 0279, Email Purpose: To compare clinical outcomes following gel stent implantation via ab externo and ab interno approaches in patients with refractory glaucoma. Patients and Methods: This retrospective study included 203 eyes of 185 patients aged ≥ 45 years who underwent Xen gel stent implantation as a standalone procedure for medically uncontrolled glaucoma (intraocular pressure (IOP) ≥ 18 mmHg) despite maximum tolerable IOP-lowering medications. One hundred and five eyes underwent gel stent implantation via ab interno approach and 98 via ab externo. Patients with prior conjunctival-incisional glaucoma or cataract surgery were also included. Study parameters were reduction in IOP and number of IOP-lowering medications from baseline to 3, 6, 9 and 12 months postoperatively. Results: There were no statistically significant differences in the age, sex, preoperative IOP, number of IOP-lowering medications or cup–disc ratio between the ab interno and ab externo groups at baseline (p > 0.05). At all postoperative time points, mean IOP and percentage reduction from baseline were comparable in both groups (p > 0.05) except at postoperative 6 months when the outcomes were significantly better (p 0.05). The mean number of IOP-lowering medications was comparable in both groups at all time points. Conclusion: The Xen gel stent, whether implanted ab interno or ab externo, is effective in reducing IOP and dependence on topical medications in eyes with refractory glaucoma. The stent may be used in both phakic and pseudophakic patients and is a reasonable option for patients with prior failed trabeculectomy. Keywords: subconjunctival gel stent, gel stent, Xen gel stent, ab interno gel stent implantation, ab externo gel stent implantation, refractory glaucoma Innovative minimally invasive glaucoma surgery (MIGS) techniques and devices have been developed in recent years for the surgical management of glaucoma. 1 MIGS procedures have been documented to have better safety and more rapid postoperative recovery than traditional glaucoma surgeries. 2,3 Several MIGS devices work by improving outflow through the physiological pathway of Schlemm's canal or the suprachoroidal space. 4,5 The Xen Gel Stent (Xen 45, Allergan Inc., Irvine, CA), intended for management of refractory glaucoma, bypasses conventional outflow pathways by creating a filtration route from the anterior chamber to the subconjunctival space, in a manner similar to trabeculectomy. 6,7 In the majority of the gel stent studies published to date, an ab-interno implantation technique has been used, an approach used during clinical trials. With this approach, significant reduction in intraocular pressure (IOP) and the number of IOP-lowering medications have been reported. 8–10 As glaucoma surgeons have gained experience with this device, some have reported using an alternative, off-label, ab externo, approach to implantation. The potential advantages of an ab-externo approach include reduced surgical manipulation within the anterior chamber, elimination of corneal incisions, optional use of viscoelastic, and decreased likelihood of the distal end of the gel stent becoming embedded in Tenon's capsule. 7 Additionally, an ab externo approach makes possible the implantation of a gel stent in eyes in which it cannot be implanted with an ab interno approach due to corneal opacity or scarring in the superonasal quadrant. However, there are limited data available on the safety and efficacy of the ab externo approach to gel stent implantation. The purpose of the present study is to compare clinical outcomes following gel stent implantation via an ab externo approach to the conventional ab interno approach in patients with refractory glaucoma on maximum tolerable medical therapy, including eyes with or without prior cataract surgery and with or without prior conjunctival-incisional glaucoma surgery. This single center, retrospective study included chart records of consecutive patients with refractory glaucoma who underwent ab interno -Abstract Truncated-